Niagen Bioscience, Inc. Common Stock (NAGE) — Analysis Summary
Niagen Bioscience, Inc. Common Stock (NAGE) has a market cap of $212.85M with year-over-year revenue growth of +29.9%. Net margin stands at 13.4%. The stock trades at a P/E ratio of 13.3.
Key Takeaways
- Revenue changed +29.9% year-over-year
- Net margin of 13.4%
- P/E ratio of 13.3
Compared to other companies in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS sector, NAGE posted revenue growth of +29.9% and trades at a P/E of 13.3.
Niagen Bioscience, Inc. Common Stock (NAGE)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Sector
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Employees
117
Headquarters
LOS ANGELES, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.